Skip to content
Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Center for
U.S. Healthcare
Policy Research
Research
areas
Research areas
Value
Access
Innovation
All content
Transparency Report
& Issue Briefs
Perspectives
& insights
About us
Menu
Center for
U.S. Healthcare
Policy Research
Research
areas
Research areas
Value
Access
Innovation
All content
Transparency Report
& Issue Briefs
Perspectives
& insights
About us
Show Search
Search Query
Clear
Submit Search
Dictate search request
Listening...
Search Results
No Results
See all results
Sorry, I don't understand. Please try again
Home
/
Content library
Content library
Explore all content
Search Query
Submit Search
Clear
Dictate search request
Sorry, I don't understand. Please try again
Date
All (79)
2026 (20)
2025 (41)
2024 (7)
2023 (3)
2022 (3)
2021 (1)
2020 (1)
2019 (1)
2018 (1)
2017 (1)
Category
All (79)
Perspectives & insights (33)
Research (23)
Transparency Report & Issue Briefs (24)
Tag
All (79)
340B (13)
Access (25)
Innovation (1)
Innovation & R&D (9)
Insurance Design Reform & PBMs (2)
Prescription Drug Affordability Boards (PDABs) and Upper Payment Limits (UPLs) (1)
Research utilization (1)
Resource Utilization and Patient Access (1)
Transparency (22)
Value (7)
Value Assessment (3)
There are 79 results that match your search.
Filters
Date
All (79)
2026 (20)
2025 (41)
2024 (7)
2023 (3)
2022 (3)
2021 (1)
2020 (1)
2019 (1)
2018 (1)
2017 (1)
Category
All (79)
Perspectives & insights (33)
Research (23)
Transparency Report & Issue Briefs (24)
Tag
All (79)
340B (13)
Access (25)
Innovation (1)
Innovation & R&D (9)
Insurance Design Reform & PBMs (2)
Prescription Drug Affordability Boards (PDABs) and Upper Payment Limits (UPLs) (1)
Research utilization (1)
Resource Utilization and Patient Access (1)
Transparency (22)
Value (7)
Value Assessment (3)
Newest
Newest
Oldest
Relevance
Perspectives & insights
July 17, 2026
HRSA finds 340B covered entity purchases have eclipsed $100 billion
Read more
Perspectives & insights
June 23, 2026
How should drug prices be specified in U.S. economic analyses?
Read more
Perspectives & insights
June 17, 2026
How have new medicines improved health and life expectancy in the United States?
This is the first blog of a three-part series highlighting the Value of Health in the United States.
Read more
Transparency Report & Issue Briefs
May 11, 2026
Full text: The value of medicines in the U.S.
Johnson & Johnson Issue Brief
Read more
Perspectives & insights
May 11, 2026
Blog: The value of medicines in the U.S.
Read more
Transparency Report & Issue Briefs
May 11, 2026
Infographic: The value of medicines in the U.S.
Read more
Transparency Report & Issue Briefs
The value of medicines in the U.S.
Read more
Access
May 1, 2026
Surge in out-of-pocket costs for commercially insured patients places heaviest burden on the most vulnerable
Read more
Access
April 22, 2026
Study of rebate-pass-through legislation suggests association with lower patient costs
Read more
Perspectives & insights
March 25, 2026
Who’s driving the surge in the 340B Program?
Read more
Load more
